The current state of biomarkers of mild traumatic brain injury

Han Jun Kim, Jack W. Tsao, Ansley Stanfill

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Mild traumatic brain injury (mTBI) is a common occurrence, with over 3 million cases reported every year in the United States. While research into the underlying pathophysiology is ongoing, there is an urgent need for better clinical guidelines that allow more consistent diagnosis of mTBI and ensure safe return-to-play timelines for athletes, nonathletes, and military personnel. The development of a suite of biomarkers that indicate the pathogenicity of mTBI could lead to clinically useful tools for establishing both diagnosis and prognosis. Here, we review the current evidence for mTBI biomarkers derived from investigations of the multifactorial pathology of mTBI. While the current literature lacks the scope and size for clarification of these biomarkers' clinical utility, early studies have identified some promising candidates.

Original languageEnglish (US)
JournalJCI insight
Volume3
Issue number1
DOIs
StatePublished - Jan 11 2018

Fingerprint

Brain Concussion
Biomarkers
Military Personnel
Athletes
Virulence
Guidelines
Pathology
Research

Cite this

The current state of biomarkers of mild traumatic brain injury. / Kim, Han Jun; Tsao, Jack W.; Stanfill, Ansley.

In: JCI insight, Vol. 3, No. 1, 11.01.2018.

Research output: Contribution to journalReview article

@article{8c0a51d30d934750a425cd2053e95218,
title = "The current state of biomarkers of mild traumatic brain injury",
abstract = "Mild traumatic brain injury (mTBI) is a common occurrence, with over 3 million cases reported every year in the United States. While research into the underlying pathophysiology is ongoing, there is an urgent need for better clinical guidelines that allow more consistent diagnosis of mTBI and ensure safe return-to-play timelines for athletes, nonathletes, and military personnel. The development of a suite of biomarkers that indicate the pathogenicity of mTBI could lead to clinically useful tools for establishing both diagnosis and prognosis. Here, we review the current evidence for mTBI biomarkers derived from investigations of the multifactorial pathology of mTBI. While the current literature lacks the scope and size for clarification of these biomarkers' clinical utility, early studies have identified some promising candidates.",
author = "Kim, {Han Jun} and Tsao, {Jack W.} and Ansley Stanfill",
year = "2018",
month = "1",
day = "11",
doi = "10.1172/jci.insight.97105",
language = "English (US)",
volume = "3",
journal = "JCI insight",
issn = "2379-3708",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - The current state of biomarkers of mild traumatic brain injury

AU - Kim, Han Jun

AU - Tsao, Jack W.

AU - Stanfill, Ansley

PY - 2018/1/11

Y1 - 2018/1/11

N2 - Mild traumatic brain injury (mTBI) is a common occurrence, with over 3 million cases reported every year in the United States. While research into the underlying pathophysiology is ongoing, there is an urgent need for better clinical guidelines that allow more consistent diagnosis of mTBI and ensure safe return-to-play timelines for athletes, nonathletes, and military personnel. The development of a suite of biomarkers that indicate the pathogenicity of mTBI could lead to clinically useful tools for establishing both diagnosis and prognosis. Here, we review the current evidence for mTBI biomarkers derived from investigations of the multifactorial pathology of mTBI. While the current literature lacks the scope and size for clarification of these biomarkers' clinical utility, early studies have identified some promising candidates.

AB - Mild traumatic brain injury (mTBI) is a common occurrence, with over 3 million cases reported every year in the United States. While research into the underlying pathophysiology is ongoing, there is an urgent need for better clinical guidelines that allow more consistent diagnosis of mTBI and ensure safe return-to-play timelines for athletes, nonathletes, and military personnel. The development of a suite of biomarkers that indicate the pathogenicity of mTBI could lead to clinically useful tools for establishing both diagnosis and prognosis. Here, we review the current evidence for mTBI biomarkers derived from investigations of the multifactorial pathology of mTBI. While the current literature lacks the scope and size for clarification of these biomarkers' clinical utility, early studies have identified some promising candidates.

UR - http://www.scopus.com/inward/record.url?scp=85051763195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051763195&partnerID=8YFLogxK

U2 - 10.1172/jci.insight.97105

DO - 10.1172/jci.insight.97105

M3 - Review article

VL - 3

JO - JCI insight

JF - JCI insight

SN - 2379-3708

IS - 1

ER -